Jetrea Market Report 2026

Jetrea Market Overview

• The Jetrea market growth in the historic period has been driven by limitations of surgical vitrectomy, rising prevalence of age related eye disorders • Market expansion is supported by aging global population, growth in retinal specialty clinics • Growth Driver: Rising Prevalence Of Retinal Diseases Driving The Growth Of The Jetrea Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Jetrea Market?

Jetrea (ocriplasmin), a pharmacologic agent, indicated for the treatment of vitreomacular adhesion (VMA) and macular hole. Jetrea works by enzymatically degrading the proteins responsible for the abnormal adhesion between the vitreous body and the macula, a condition that can lead to visual impairment. The main indications in the jetrea market are vitreomacular traction, symptomatic vitreomacular adhesion, and combination therapy. Vitreomacular traction (VMT) refers to a condition where the vitreous gel, which fills the inside of the eye, adheres abnormally to the macula, the central part of the retina responsible for sharp, detailed vision. The different patient demographics include adult patients, elderly patients, and high-risk groups, and several distribution channels including direct sales, pharmaceutical wholesalers, online pharmacies, and international markets. The several end users encompass ophthalmologists, hospitals and clinics, outpatient surgical centers, and research institutions.

What Is The Jetrea Market Growth Forecast?

The growth in the forecast period can be attributed to aging global population, growth in retinal specialty clinics, increased screening for macular conditions, preference for office based treatments, continued innovation in ophthalmic enzymes. Major trends in the forecast period include increasing adoption of pharmacologic vitreolysis, rising preference for minimally invasive retinal treatments, growing diagnosis of vitreomacular disorders, shift toward enzyme based ophthalmic therapies, expansion of outpatient retinal care.

Global Jetrea Market Segmentation

1) By Indication: Vitreomacular Traction, Symptomatoc Vitreomacular Adhesion, Combination Therapy 2) By Patient Demographics: Adult Patients, Elderly Patients, High-Risk Groups 3) By Distribution Channel: Direct Sales, Pharmaceutical Wholesalers, Online Pharmacies, International Markets 4) By End User: Ophthalmologists, Hospitals And Clinics, Outpatient Surgical Centres, Research Institutions

What Are The Drivers Of The Jetrea Market?

Increasing prevalence of retinal diseases is expected to propel the growth of the jetrea market going forward. Retinal diseases are a group of conditions that affect the retina, the light-sensitive tissue at the back of the eye, potentially leading to vision loss or blindness if untreated. The increasing prevalence of retinal diseases is driven by aging populations, rising rates of diabetes, and greater exposure to risk factors like hypertension and lifestyle changes. Jetrea (ocriplasmin) is used in the treatment of vitreomacular traction and macular holes, helping address specific retinal diseases associated with the increasing prevalence of age-related and diabetic eye conditions. For instance, in May 2024, according to The Royal College of Ophthalmologists, a UK-based public college, the prevalence of sight loss and blindness caused by age-related macular degeneration (AMD) is projected to rise to 29.7% by 2050, up from 23.1% in 2024, with the affected population increasing from approximately 445,809 individuals to an estimated 1.23 million. Therefore, increasing prevalence of retinal diseases drives the jetrea industry. The growing number of clinical trials is expected to fuel the expansion of the jetrea market going forward. Clinical trials refer to structured research studies conducted to evaluate the effectiveness, safety, and potential side effects of medical treatments, drugs, or devices in humans. The increasing number of clinical trials reflects the growing complexity of healthcare needs, advancements in science, and the broader scope of medical research. Jetrea, with its innovative mechanism for treating symptomatic vitreomacular adhesion (sVMA), supports clinical trials by providing a targeted therapeutic option that enhances the evaluation of efficacy and safety in resolving this condition, thereby advancing research in retinal health. For instance, in October 2024, according to ClinicalTrials.gov, a US-based government clinical trials registry, during 2023 a total of 39,710 new studies were registered, bringing the cumulative total to 477,203 studies by the end of 2023, compared to 38,023 new studies registered during 2022 which brought the cumulative total to 437,493 studies by the end of 2022. Therefore, the rising number of clinical trials is driving the growth of the jetrea industry. Rising personalized medicine is expected to propel the growth of the jetrea market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare strategies to the individual characteristics of each patient, such as their genetic makeup, environment, and lifestyle, to achieve the most effective and precise outcomes. The rising personalized medicine is due to advancements in genomic technologies, increased understanding of molecular biology, growing availability of precision diagnostic tools, and the demand for targeted therapies that improve patient outcomes while minimizing side effects. Personalized medicine benefits from Jetrea's precise mechanism of action, which addresses specific retinal conditions like symptomatic vitreomacular adhesion (sVMA) by offering a non-surgical, tailored treatment option that aligns with the unique needs of individual patients. For instance, in April 2025, according to the Drug Information Association (DIA) Global Forum, a US-based non-profit organization, as of early 2025 the FDA has approved over 30 cell and gene therapies, and industry experts anticipate 30-50 additional cell and gene therapy approvals by 2030. Therefore, rising personalized medicine drives the jetrea industry.

Key Players In The Global Jetrea Market

Major companies operating in the jetrea market are Oxurion NV (Formerly ThromboGenics Inc.)

Regional Insights

North America was the largest region in the Jetrea market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Jetrea Market?

The jetrea market consists of sales of jetrea as single use intravitreal injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Jetrea Market Report 2026?

The jetrea market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the jetrea industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.